Certainties and Uncertainties About Denosumab Discontinuation

Bone Mineral Density Changes After 1 Year of Denosumab Discontinuation in Postmenopausal Women with Long-Term Denosumab Treatment for Osteoporosis

(2018) Albrecht Werner Popp et al.   CALCIFIED TISSUE INTERNATIONAL

Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates

(2018) Anne M. Horne et al.   CALCIFIED TISSUE INTERNATIONAL

Multiple Vertebral Fractures Following Denosumab Discontinuation: Are We Exaggerating?

(2018) Athanasios D. Anastasilakis et al.   CALCIFIED TISSUE INTERNATIONAL

Vertebral Fractures Following Denosumab Discontinuation in Patients with Prolonged Exposure to Bisphosphonates

(2018) Liana Tripto-Shkolnik et al.   CALCIFIED TISSUE INTERNATIONAL

Underestimation of Vertebral Fractures After Denosumab Discontinuation

(2018) Olivier Lamy et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study

(2018) Kenneth G Saag et al.   Lancet Diabetes & Endocrinology

Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment

(2017) Athanasios D Anastasilakis et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension

(2017) Steven R Cummings et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases

(2017) Athanasios D Anastasilakis et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Response to Letter: Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation

(2017) Olivier Lamy et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates

(2017) B. Uebelhart et al.   OSTEOPOROSIS INTERNATIONAL

Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures

(2017) T. Lehmann et al.   OSTEOPOROSIS INTERNATIONAL

Observations following discontinuation of long-term denosumab therapy

(2017) M. R. McClung et al.   OSTEOPOROSIS INTERNATIONAL

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

(2017) Henry G Bone et al.   Lancet Diabetes & Endocrinology

Cancel the denosumab holiday

(2016) M. R. McClung   OSTEOPOROSIS INTERNATIONAL

Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports

(2015) B. Aubry-Rozier et al.   OSTEOPOROSIS INTERNATIONAL

Multiple clinical vertebral fractures following denosumab discontinuation

(2015) A. D. Anastasilakis et al.   OSTEOPOROSIS INTERNATIONAL

Rebound-associated vertebral fractures after discontinuation of denosumab—from clinic and biomechanics

(2015) A. W. Popp et al.   OSTEOPOROSIS INTERNATIONAL

The Waning of Teriparatide Effect on Bone Formation Markers in Postmenopausal Osteoporosis Is Associated with Increasing Serum Levels of DKK1

(2011) Davide Gatti et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass

(2011) Henry G. Bone et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect

(2010) John A Eisman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial

(2010) Paul D. Miller et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The effect of cessation of raloxifene treatment on bone turnover in postmenopausal women

(2009) K.E. Naylor et al.   BONE

Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis

(2009) P. J. Meunier et al.   OSTEOPOROSIS INTERNATIONAL